Takeda and Lundbeck had prepared to advertise that their latest antidepressant Brintellix (Vortioxetine) could give patients a cognitive boost and help them think and pay attention. While the FDA agreed that cognitive dysfunction in major depressive disorder is “a legitimate target for drug development,” they did not approve the claims for this drug.
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.